Eastern Europe Biopharmaceuticals Market

The Eastern Europe Biopharmaceuticals market is estimated to grow at a steady growth rate during the forecast period. 

Development of biopharmaceutical product is being undertaken by increasing the number of competitors in the pharmaceutical industry. Market players are more focusing on expanding the biologics pipeline, relying on the fact that commercialization of biopharmaceuticals will reduce the usage of traditional small molecular drugs. Pharmaceutical industries mainly rely on biopharmaceuticals for profits and innovation.

Advancement in biomedical science holds vast potential for the growth of the biopharmaceuticals market. The ability of these drugs to treat chronic diseases which were earlier untreatable is increasing its demand enormously and also increases the profit margin for manufacturers. Biopharmaceutical drugs need to be stored in cold storage which limits their transport to rural areas and hence hindering the growth of the market.

The Eastern Europe biopharmaceuticals market is segmented based on products into Monoclonal Antibodies (mAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte colony-stimulating factor (G-CSF), Interferon and Human growth hormones (HGH). Monoclonal antibodies segment holds the highest number of shares in the product sector. Based on therapeutics, the market is bifurcated into Neurology, Infectious diseases, Diabetes, Oncology, Cardiovascular and other therapeutic areas. In terms of therapeutic application, oncology is the largest segment in the biopharmaceuticals market.

Based on geography, the market is analyzed under various countries, namely, Ukraine, Poland, Romania, Czech Republic, Hungary and Rest of Eastern Europe.

Merck & Co., Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, Inc., Sanofi, Amgen Inc., AbbVie Inc., Biogen Idec, Bayer AG, Johnson & Johnson Services, Pfizer, Inc., and Novartis AG are some of the leading players in the market for biopharmaceuticals.